• Users Online: 117
  • Print this page
  • Email this page

Current Issue

July-September 2018| Vol 1| Issue 1

Original Article

Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series

Background: Tumors with deficient mismatch repair (dMMR) have a favorable immunological phenotype permitting exploitation by immunotherapies. We aimed to assess our institutional experience o...


Original Article

The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes

Background: Immune checkpoint inhibitors (ICPIs) are gaining more popularity as a treatment for advanced cancers. However, immune-related adverse events (irAEs) limit their use. We aimed to a...


Original Article

Erlotinib in patients with advanced non-small cell lung cancer in Middle Eastern population

Background: Although erlotinib is widely used in the management of non-small cell lung cancer (NSCLC), no prior studies were conducted in Middle Eastern population. Our study aims at evaluati...


Review Article

Pneumonitis after precision oncology therapies: A concise review

With greater understanding of the molecular biology of cancer, precision oncology therapies are becoming increasingly prevalent. Adverse events associated with these therapies may cause significant ...


Review Article

Understanding the toxicity of cancer immunotherapies: Use of patient-reported outcomes

Immunotherapy has transformed the treatment of various cancers by strengthening suppressed immune systems for antitumor effects. However, altering the immune balance also produces unconventional adv...


View All Articles in the Current Issue

Journal of Immunotherapy and Precision Oncology, a publication of Global Academy for Health Sciences, is a peer-reviewed print + online Quarterly journal.

Features of Manuscript Management System

  • Online submission
  • Wider visibility through open access
  • Higher impact
  • Prompt review
CALL FOR PAPERS